These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment]. Langfort R; Rudziński P; Burakowska B Pneumonol Alergol Pol; 2010; 78(1):33-46. PubMed ID: 20162517 [TBL] [Abstract][Full Text] [Related]
3. [Diagnosis and treatment of the neuroendocrine tumors of the lung]. Gálffy G Magy Onkol; 2018 Jul; 62(2):113-118. PubMed ID: 30027939 [TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of typical and atypical lung carcinoids. Pusceddu S; Lo Russo G; Macerelli M; Proto C; Vitali M; Signorelli D; Ganzinelli M; Scanagatta P; Duranti L; Trama A; Buzzoni R; Pelosi G; Pastorino U; de Braud F; Garassino MC Crit Rev Oncol Hematol; 2016 Apr; 100():167-76. PubMed ID: 26917456 [TBL] [Abstract][Full Text] [Related]
5. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung. Wolin EM Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769 [TBL] [Abstract][Full Text] [Related]
6. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Swarts DR; Ramaekers FC; Speel EJ Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738 [TBL] [Abstract][Full Text] [Related]
7. Carcinomas of the lung with neuroendocrine differentiation. Carter D; Yesner R Semin Diagn Pathol; 1985 Nov; 2(4):235-54. PubMed ID: 3039628 [TBL] [Abstract][Full Text] [Related]
16. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Igarashi T; Jiang SX; Kameya T; Asamura H; Sato Y; Nagai K; Okayasu I Mod Pathol; 2004 Oct; 17(10):1259-67. PubMed ID: 15154011 [TBL] [Abstract][Full Text] [Related]
17. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Caplin ME; Baudin E; Ferolla P; Filosso P; Garcia-Yuste M; Lim E; Oberg K; Pelosi G; Perren A; Rossi RE; Travis WD; Ann Oncol; 2015 Aug; 26(8):1604-20. PubMed ID: 25646366 [TBL] [Abstract][Full Text] [Related]
18. Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. Gridelli C; Rossi A; Airoma G; Bianco R; Costanzo R; Daniele B; Chiara GD; Grimaldi G; Irtelli L; Maione P; Morabito A; Piantedosi FV; Riccardi F Cancer Treat Rev; 2013 Aug; 39(5):466-72. PubMed ID: 22818212 [TBL] [Abstract][Full Text] [Related]
19. Recent Advances in the Management of Typical and Atypical Lung Carcinoids. Prinzi N; Rossi RE; Proto C; Leuzzi G; Raimondi A; Torchio M; Milione M; Corti F; Colombo E; Prisciandaro M; Cascella T; Spreafico C; Beninato T; Coppa J; Lo Russo G; Di Bartolomeo M; de Braud F; Pusceddu S Clin Lung Cancer; 2021 May; 22(3):161-169. PubMed ID: 33618994 [TBL] [Abstract][Full Text] [Related]
20. Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study. Hechtman JF; Beasley MB; Kinoshita Y; Ko HM; Hao K; Burstein DE Hum Pathol; 2013 Jul; 44(7):1400-5. PubMed ID: 23416030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]